Evaluation of EGFR Mutation Testing Concordance Between Next-Generation Sequencing and Biocartis Idylla…

Cohort studyCytopathology : official journal of the British Society for Clinical Cytology· Jul 2026

Evaluation of EGFR Mutation Testing Concordance Between Next-Generation Sequencing and Biocartis Idylla Console in NSCLC.

Vidusha Wijesinghe, Mary Jones, Leonie Wheeldon

Molecular PathologyCohort studyQ3IF 1.2

Idylla epidermal growth factor receptor testing matched next-generation sequencing in 86% of mutation-positive lung cancer samples.

Evaluation of EGFR Mutation Testing Concordance Between Next-Generation Sequencing and Biocartis Idylla Console in NSCLC.

Vidusha Wijesinghe … Leonie Wheeldon

Cytopathology · Jul 2026 · Q3 in Pathology

Purpose

The aim of this study was to evaluate the concordance of in-house epidermal growth factor receptor (epidermal growth factor receptor) mutation testing using the Biocartis Idylla (Idylla) platform compared with next-generation sequencing (next-generation sequencing) for formalin-fixed, paraffin-embedded (FFPE) and liquid based cytology (liquid based cytology) samples.

Methods

This retrospective study used data collected on patients between November 2022 and September 2024, a total of 180 samples, in which epidermal growth factor receptor mutations were tested for using MiSEQ Next generation sequencing (next-generation sequencing) platform or the Idylla Console.

n = 180 samples

86%

Results

86%

Idylla testing agreed with next-generation sequencing in most mutation-positive samples

n = 180 samples

More results

Among 180 samples tested, 14 (7.78%) expressed various epidermal growth factor receptor mutations by either next-generation sequencing and/or the Idylla platform.

However, next-generation sequencing identified 2 mutations in which Idylla was unable to identify.

More results

Whilst Idylla was able to identify one epidermal growth factor receptor Exon 21 L858R mutation in a sample in which next-generation sequencing was unable to test due to insufficient material.

With significantly lower CQ values on average 20.94 compared to 22.28 than that of FFPE samples (p = 0.00151 3.s.f).

“

Conclusion · 1 of 3

The Idylla Console demonstrates high concordance with next-generation sequencing and effectively complements molecular diagnostics in resource and time-constrained settings.

Conclusion · 2 of 3

5.5% of cases tested using the next-generation sequencing resulted in insufficient or failed testing suggesting a need for multi-platform testing.

Conclusion · 3 of 3

liquid based cytology samples, particularly with the utilisation of rapid on-site evaluation, enhance testing quality and efficiency, offering a robust alternative to FFPE samples.

Evaluation of EGFR Mutation Testing Concordance Between Next-Generation Sequencing and Biocartis Idylla Console in NSCLC.

Evaluation of EGFR Mutation Testing Concordance Between Next-Generation Sequencing and Biocartis Idylla Console in NSCLC.

Related papers